Brief: Radiopharm Theranostics Advances To Cohort 3 In 177Lu-RAD202 Phase 1 Dose Escalating Clinical Trial
08/04/2026 13:14
April 8 (Reuters) - Radiopharm Theranostics Ltd RAD.AX: RADIOPHARM THERANOSTICS ADVANCES TO COHORT 3 IN 177LU-RAD202 PHASE 1 DOSE ESCALATING CLINICAL TRIAL RADIOPHARM THERANOSTICS LTD: ON TRACK TO COMPLETE PHASE 1 DOSE ESCALATION BY END OF 2026 Source text: ID:nGNX4XZMwX Further company coverage: RAD.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Radiopharm Theranostics
See all newsBrief: Radiopharm Theranostics Advances To Cohort 3 In 177Lu-RAD202 Phase 1 Dose Escalating Clinical Trial
Brief: Radiopharm Theranostics And Siemens Healthineers Sign Clinical Supply Agreement For Rad101 In The U.S.
Brief: Radiopharm Theranostics Says RAD And Siemens Sign Clinical Supply Agreement For Rad101
Brief: Radiopharm Theranostics Doses First Patient In Phase 1/2A Clinical Study Of Betabart
Brief: Radiopharm Theranostics Says Co Increases Ownership In Radiopharm Ventures To 87.5%